Imagion Biosystems Limited ASX: IBX A S X A N N O U N C E M E N T | 1 7 N O V E M B E R 2 0 2 6 Imagion Executes First US Site Agreement for Phase 1b/2 Clinical Trial of MagSense® Imaging Agent for HER2+ Breast Cancer Key Highlights: • Imagion has executed a Clinical Trial Agreement with Regis...
IBX First Site Agreement Advances Phase 2 Trial Plans
Filed with ASX · · 4 pages · English
Release
Imagion Biosystems Ltd. on 6ix
Story so far
Earlier from Imagion Biosystems
- Cleansing Notice
- Application for quotation of securities - IBX
- IBX Announces NED Resignation & Change of Company Secretary
- Amended Appendix 4C - September 2026
- Appendix 4C and Quarterly Activities Report - September 2026
Later from Imagion Biosystems
All Imagion Biosystems news releasesFollow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems